The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis
Open accessAbstract
The American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma and Immunology Executive Committees formed the Omalizumab Joint Task Force with the purpose of reviewing the Genentech Xolair (omalizumab) clinical trials and postmarketing surveillance data on anaphylaxis and anaphylactoid reactions. Using the definition of anaphylaxis proposed at a 2005 multidisciplinary symposia, the Omalizumab Joint Task Force concluded that 35 patients had 41 episodes of anaphylaxis associated with Xolair (omalizumab) administration between June 1, 2003, and December 31, 2005. With 39,510 patients receiving Xolair (omalizumab) during the same period of time, this would correspond to an anaphylaxis-reporting rate of 0.09% of patients. Of those 36 events for which the time of reaction was known, 22 (61%) reactions occurred in the first 2 hours after one of the first 3 doses. Five (14%) of the events after the fourth or later doses occurred within 30 minutes. Considering the timing of these 36 events, an observation period of 2 hours for the first 3 injections and 30 minutes for subsequent injections would have captured 75% of the anaphylactic reactions. The OJTF report provides recommendations for physicians who prescribe Xolair (omalizumab) on (1) the suggested wait periods after administration and (2) patient education regarding anaphylaxis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, omalizumab has been associated with anaphylactic reactions in 0.09% to 0.2% of patients, with current recommendations to monitor patients for 30 minutes following administration.1742,1743”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1742]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The estimated rate of systemic reaction from a pollen-food allergy is 10% and the estimated rate of anaphylaxis is 1.7% to 10%.1742,1919,1920”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1742]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson, N., Bock, S. A., Branum, A., Brown, S., Camargo, C. A., Cydulka, R., Galli, S., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.1303 · Cited by 2,170
Self-citationSymposium on the definition and management of anaphylaxis: summary report.
Sampson, H., Muñoz-Furlong, A., Bock, S., Schmitt, C., Bass, R., Chowdhury, B., Decker, W., Furlong, T., Galli, S., Golden, D., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.009 · Cited by 640
Self-citationThe Incidence and Management of Infusion Reactions To Infliximab: A Large Center Experience
Cheifetz, A. S., Smedley, M. V., Martin, S., Reiter, M., Leone, G., Mayer, L., & Plevy, S. E. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07457.x · Cited by 491
The diagnosis and management of anaphylaxis
Lieberman, P., Kemp, S., Oppenheimer, J., Lang, D., Bernstein, I., Nicklas, R., Anderson, J. A., Bernstein, D., Bernstein, J., Fink, J., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.010 · Cited by 296
Anaphylaxis, killer allergy: Long-term management in the community
Simons, F. E. R. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.002 · Cited by 224
Self-citationMonoclonal antibodies, immunogenicity, and associated infusion reactions.
Cheifetz, A. S., & Mayer, L. (2005) · PubMed · Cited by 152
Price, K. S., & Hamilton, R. G. (2007) · Allergy and Asthma Proceedings · doi:10.2500/aap.2007.28.3003 · Cited by 143
Desensitization for drug allergy
Castells, M. (2006) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3280108716 · Cited by 122
Steele, R. H., Limaye, S., Cleland, B., Chow, J. S. F., & SURANYI, M. G. (2005) · Nephrology · doi:10.1111/j.1440-1797.2005.00389.x · Cited by 93
Baudouin, V., Crusiaux, A., Haddad, É., Schandené, L., Goldman, M., Loirat, C., & Abramowicz, D. (2003) · Transplantation · doi:10.1097/01.tp.0000073809.65502.8f · Cited by 83
Cited by
Sorted by citations
Items 201–294 of 294
Allergy to Omalizumab: Lessons from a Reaction to the Coronavirus 2019 Vaccine
Matsumoto, T., Sakurai, Y., Fujiki, T., Kusakabe, Y., Nakayama, E., Tanaka, A., Yamamoto, N., Aihara, K., Yamaoka, S., & Mishima, M. (2023) · Internal Medicine · doi:10.2169/internalmedicine.1169-22 · Cited by 4
Anaphylaxis Induced by Biologics
Joshi, S. R., & Khan, D. A. (2019) · Current Treatment Options in Allergy · doi:10.1007/s40521-019-00207-0 · Cited by 4
Lin, Y., Wang, W., Zhu, Z., Aodeng, S., Wang, L., Liu, Y., Li, J., Zha, Y., Wang, X., & Lv, W. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082848 · Cited by 4
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Connections and Unmet Needs: Severe Asthma Biologics and Osteoporosis
Furci, F., Scaramozzino, M. U., Talesa, G. R., Crea, G. G., & Pelaia, C. (2025) · Biomedicines · doi:10.3390/biomedicines13010197 · Cited by 3
Kuprys-Lipinska, I. R., & Kuna, P. (2008) · Advances in respiratory medicine · doi:10.5603/arm.27844 · Cited by 3
Lugogo, N. L., Que, L. G., Fertel, D., & Kraft, M. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4710-0.00038-9 · Cited by 3
Management of drug allergy-clinical update
Kathuria, P., & Rai, M. (2022) · Indian Journal of Allergy Asthma and Immunology · doi:10.4103/ijaai.ijaai_34_22 · Cited by 3
Inconsistences in Prescribing Epinephrine Autoinjectors
Turner, P., Patel, N., Adams, K. E., Hatcher, V. R., Bigas, P., & Golden, D. B. K. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.07.045 · Cited by 3
Tillie‐Leblond, I., Deschildre, A., Gosset, P., & Jacques de, B. L. I. C. (2012) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2012.05.006 · Cited by 3
Nanomaterials at the Biological Interphase: Protein Corona Formation and Infusion Reactions
Dar, A. I., Abidi, S. M. S., & Acharya, A. (2020) · Springer eBooks · doi:10.1007/978-981-15-4280-0_8 · Cited by 3
Secondary Prevention of Acute Rheumatic Fever and Rheumatic Heart Disease
de Dassel, J. L., LENNON, D. R., Dougherty, S., & Ralph, A. P. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-63982-8.00011-8 · Cited by 3
Omalizumab for the treatment of severe allergic asthma
Menzies-Gow, A. N., & Chung, K. F. (2008) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.4.5.543 · Cited by 3
Hypersensitivity Reactions to Monoclonal Antibodies
Liu, A. Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48551-7.00020-1 · Cited by 3
Les biothérapies en 2023 dans l’asthme sévère de l’enfant
Amat, F. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.09.002 · Cited by 2
Yang, Y., Fang, C., Jiang, Z., Su, X., & Fan, W. Q. (2026) · BMC Pediatrics · doi:10.1186/s12887-026-06595-y · Cited by 2
Expertenkonsensus zu praxisrelevanten Aspekten bei der Behandlung der chronischen Urtikaria
Bauer, A., Dickel, H., Jakob, T., Kleinheinz, A., Lippert, U., Metz, M., Schliemann, S., Schwichtenberg, U., Staubach, P., Valesky, E. M., et al. (2021) · Allergo Journal · doi:10.1007/s15007-021-4772-2 · Cited by 2
Managing Severe Adverse Reactions to Biologicals in Severe Asthma
Bălan, R.-G., Deleanu, D. M., Pintea, I., Dobrican, C. T., Man, M. A., Bocșan, I. C., & Muntean, I. A. (2023) · Biomedicines · doi:10.3390/biomedicines11123108 · Cited by 2
Effets indésirables des biothérapies de l’asthme sévère
Dargentolle, G., Georges, M., Beltramo, G., Poisson, C., & Bonniaud, P. (2024) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2024.04.001 · Cited by 2
Risks and benefits of allergen immunotherapy
Rogala, B., & Glück, J. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802457208 · Cited by 2
First Experience with Omalizumab in a Child with Severe Persistent Asthma in Turkey: Case Report
Arga, M., Bakırtaş, A., Türktaş, İ., & Demirsoy, M. S. (2010) · Turkiye Klinikleri Journal of Medical Sciences · doi:10.5336/medsci.2009-13351 · Cited by 2
Herrera-García, J. C., Sánchez-Casas, G. A., Jaramillo-Arellano, L. E., Lechuga-Hernández, S., Carreto-Sulvaran, C., Arellano-Montellano, E. I., & Contreras-Andrade, R. I. (2015) · Medicina Interna de México · Cited by 2
The Importance of IgE and the Uses of Anti-IgE
Güvenir, H., Cingi, C., Jovančević, L., & Scadding, G. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-50899-9_36 · Cited by 2
Asthma Phenotypes and Current Biological Treatments
Gülşen, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97376 · Cited by 2
Seth, D., & Kamat, D. (2018) · Pediatric Annals · doi:10.3928/19382359-20180920-02 · Cited by 2
Highlights in nonhymenoptera anaphylaxis
Scherer, K., Ballmer-Weber, B. K., & Bircher, A. J. (2008) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32830638df · Cited by 2
Omalizumab: a broader role in dermatology? Evidence and the road ahead
Bubna, A. K., & Viplav, V. (2025) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.25.08144-7 · Cited by 1
The Use of Omalizumab in Chronic Urticaria: Available Data and Future Aspects of Anti-IgE Treatment
Ye, Y. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97226 · Cited by 1
Schwere Anaphylaxie auf Omalizumab
Keidel, F., Wölbing, P., & Schäkel, K. (2025) · Die Dermatologie · doi:10.1007/s00105-025-05542-9 · Cited by 1
Updates in the Management of Peanut Allergy
Mustafa, S. S., Anagnostou, A., & Greenhawt, M. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-050224-121037 · Cited by 1
Anaphylaxis Epidemiology and Risk Factors
Patel, N. R., & Wang, J. (2026) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2026.01.001 · Cited by 1
Drugs that act on the immune system
Braun, F., Rifaie, N., Broering, D. C., & Behrend, M. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32037-x · Cited by 1
Immunologic Reactions to Medications
Stitt, J. M., & Dreskin, S. C. (2015) · Springer eBooks · doi:10.1007/978-3-319-20790-2_129-1 · Cited by 1
A new urticarial rash, diarrhoea and refractory hypotension in a man with a history of migraines
Lamb, L., & Lowe, D. M. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-5-451 · Cited by 1
Özdemır, Ö. (2018) · Medeniyet Medical Journal · doi:10.5222/mmj.2018.00087 · Cited by 1
Anaphylaxis due to antiallergic and antiasthmatic biologics
Furci, F., Luxi, N., Senna, G., & Trifirò, G. (2023) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000937 · Cited by 1
Omalizumab in food allergy: Risks and benefits
Mustafa, S. S., & Sokol, K. C. (2025) · Journal of Food Allergy · doi:10.2500/jfa.2025.7.250004 · Cited by 1
C4 Drugs for the treatment of airway disease
Barnes, P. J. (2011) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0346-0136-8_19 · Cited by 1
Chen, S.-S., Barankiewicz, T. J., Yang, Y.-M., Goebel, P., & Liu, F. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2008.06.008 · Cited by 1
Pelaia, G., Vatrella, A., & Maselli, R. (2016) · Springer eBooks · doi:10.1007/978-3-319-46007-9_4 · Cited by 1
Frequency of Advers Reactions After Subcutaneous Allergen Immunotherapy In Children
Şaşihüseyinoğlu, A. Ş., Doğruel, D., & Altıntaş, D. U. (2020) · ENT Updates · doi:10.32448/entupdates.811534 · Cited by 1
Mechanisms and Practical Use of Biologic Therapies for Allergy and Asthma Indications
Damask, C. C., & Franzese, C. B. (2021) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2021.04.003 · Cited by 1
Barton, C. R. (2014) · doi:10.18297/etd/80 · Cited by 1
Réactions d’hypersensibilité dues aux agents modifiant la réponse biologique (biologicals)
Bircher, A. J., & Scherer, K. (2009) · Revue française d'allergologie · doi:10.1016/j.reval.2009.01.025 · Cited by 1
Severe Asthma in Children and Young People
Lawton, A., Russell-Jones, E., & Gupta, A. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00251-1 · Cited by 1
Dahlström, J., & Venemalm, L. (2011) · Wiley eBooks · doi:10.1002/9781118075685.ch12
Monoclonal Antibodies in the Treatment of Asthma
Whelan, G. J. (2012) · Wiley eBooks · doi:10.1002/9781118229019.ch22
ALLERGY TO PETS; MOLECULAR APPROACHES FOR IMPROVED DIAGNOSTICS AND VACCINATION
Nilsson, O. (2012) · Figshare
Omalizumab Therapy for Allergic Diseases
(2013) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608057184113010006
Update on Clinical Options for the Management of Allergic Rhinitis
Nasir, M., & Grant, J. A. (2011) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s6375
Omalizumab (Xolair®) for Treatment of Poorly Controlled Asthma
Bossard, M. K., & Wagner, C. W. (2011) · Journal of Asthma & Allergy Educators · doi:10.1177/2150129711421198
Allergies aux médicaments des biothérapies : les données épidémiologiques
Demoly, P. M. (2009) · Revue française d'allergologie · doi:10.1016/j.reval.2009.01.008
Specific Immunotherapy in Food Allergy — Towards a Change in the Management Paradigm
Lucas, J. M., Moreno‐Salvador, A., & García‐Marcos, L. (2015) · InTech eBooks · doi:10.5772/59105
Brożek, J., Bousquet, J., Baena-Cagnani, E., Bonini, S., Canonica, G. W., Casale, T. B., van Wijk, R. G., Ohta, K., Zuberbier, T., & Schünemann, H. J. (2010)
Turnip rape and oilseed rape allergy in children with atopic dermatitis
Poikonen, S. (2008) · Tampere University Institutional Repository (Tampere University)
Special Therapeutic Options and Substances in the Treatment of Atopic Eczema
Ring, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-22243-1_5
Anti-immunoglobulin E (IgE) Therapy
Stokes, J. R., & Casale, T. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-30835-7_40
Innovation thérapeutique dans l'asthme : cas du dupilumab
de Roucy, R. (2015) · HAL
Canonica, G. W., Casale, T. B., Faaaai, Mohapatra, S. S., Bousquet, J. J., & Holgate, S. T. (2008)
Toxicant-Induced Immunological Reactions
Stitt, J. M., & Dreskin, S. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-20790-2_129-2
INVITED REVIEW SERIES: HOW TO SET UP PULMONARY SUBSPECIALTY SERVICES
Colt, H. G. (2010)
Anti IgE Therapy in Chronic Urticaria
Ertaş, R. (2017) · InTech eBooks · doi:10.5772/68015
Estelle, F., & Simons, R. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0271-2.00061-4
Unerwünschte Arzneimit- telreaktionen an der Haut
Verlag, S. M., Bircher, A. J., Poliklinik, A., Klinik, D., & Basel, U. (2009)
Modern Molecular Therapies for Application in Managing Childhood Asthma
Hoch, H. E., Anderson, W. C., & Szefler, S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-44887-1.00048-1
Biologic and Emerging Therapies for Allergic Disease
Kwong, C. G., & Stokes, J. R. (2018) · Springer eBooks · doi:10.1007/978-3-319-58726-4_43-1
Immunotherapy and Immunomodulators
Akar-Ghibril, N., Naja, A. S., & Phipatanakul, W. (2019) · Springer eBooks · doi:10.1007/978-3-030-27431-3_7
Potential Therapeutic Options for Severe Asthma in Children: Lessons from Adult Trials
Abrams, E. M., Hoch, H. E., Becker, A. B., & Szefler, S. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-27431-3_14
Medical Treatment of Nasal Polyposis
Kuzucu, İ., Güler, İ., & Muluk, N. B. (2019) · Springer eBooks · doi:10.1007/978-3-030-21217-9_44
Stokes, J. R., & Casale, T. B. (2014) · Elsevier eBooks · doi:10.1016/b978-0-323-08593-9.00093-0
In-Office Preparedness for Anaphylaxis
Banta, E. M., & Aquino, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-43205-8_6
How Does Nasal Polyp Formation Relate to Immunomodulatory Effects?
Altın, F., Cingi, C., & Toppila-Salmi, S. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-50899-9_35
Research Progress of Omalizumab in the Treatment of Allergic Asthma
马, 晓. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.112099
Belan, E. B., Садчикова, Т. Л., & Antonov, U. V. (2009) · Russian Journal of Allergy · doi:10.36691/rja880
Biologic and Emerging Therapies for Allergic Disease
Kwong, C. G., & Stokes, J. R. (2019) · Springer eBooks · doi:10.1007/978-3-030-05147-1_43
(2008) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32830abac8
Marshik, P. L. (2014) · Springer eBooks · doi:10.1007/978-1-4614-9194-1_249
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.01180-x
Treatment of urticaria and angioedema
Xu, J., & Shih, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95061-9.00046-1
Cutaneous Adverse Reactions to Biologic Agents
Choo, K. J. L., & Yeo, Y. W. (2022) · Updates in clinical dermatology · doi:10.1007/978-3-031-09388-3_24
Special Therapeutic Options and Substances in the Treatment of Atopic Eczema
Eyerich, K., & Ring, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-12499-0_7
Treatment with biological products for chronic urticaria
Ye, Y. (2023) · Journal of Korean Medical Association · doi:10.5124/jkma.2023.66.9.537
Self-administration of biologicals for severe asthma: insights for clinicians
Menzella, F., Lombardi, C., & Cottini, M. (2024) · Minerva Respiratory Medicine · doi:10.23736/s2784-8477.23.02079-x
SAFETY OF OMALIZUMAB IN DIFFERENT PATIENT POPULATIONS
Kondrakhin, A. P., Maksimov, M. L., & Shnaider, K. O. (2024) · Bulletin Biomedicine and sociology · doi:10.26787/nydha-2618-8783-2024-9-2-59-65
Villarreal-González, R. V., Perea-Valle, P., Fraga-Olvera, A., Lara, A. Á., Delgado-Bañuelos, A., Serrano, C. A. C., Rosas, C., Alonso-Bello, C. D., Rico-Solís, G. A., Ochoa-García, I. V., et al. (2025) · Revista Alergia México · doi:10.29262/fsaxnm03
Mahashur, A. (2025) · PULMON · doi:10.4103/pulmon.pulmon_4_25
Bullous Pemphigoid Post Immune Checkpoint Inhibitor Therapy
Wang, H. Y., Aung, P. P., & Patel, A. B. (2025) · Springer eBooks · doi:10.1007/978-3-031-83533-9_2
Bubna, A. K. (2025) · Springer eBooks · doi:10.1007/978-981-95-3791-4_39
Epithélium bronchique de l'enfant asthmatique sévère
Bourée, A. (2016) · theses.fr (ABES) · doi:10.70675/b897efc1zfaa4z40f6z853ez154994d73746
Progress in anti-IgE monoclonal antibody targeting therapy for allergic bronchial asthma: A review
Li, X., Xu, J., Zhao, P., & He, S. (2026) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2026.08.001
Dogra, S., Kaur, S., & Kumaran, M. S. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2726425
Han, J., Zou, Z., Wu, S., & Chen, B. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1795193
Inner-City Anti-IgE Therapy for Asthma (ICATA/ICAC-08)
Busse, W. (2013) · ImmPort · doi:10.21430/m3v7caz3np
Metadata
- Authors
- Cox, L., Platts-Mills, T. A. E., Finegold, I., Schwartz, L. B., Simons, F. E. R., & Wallace, D. V.
- Affiliations
- Nova Southeastern University (US)
- St. Luke's-Roosevelt Hospital Center (US)
- Virginia Commonwealth University (US)
- University of Manitoba (CA)
- Corresponding author
- Cox, Linda
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2007-12
- Volume
- 120
- Issue
- 6
- Pages
- 1373-1377
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2010946738
- Cited by
- 295
- References
- 14
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 6 · 2023: 13 · 2022: 10 · 2021: 13 · 2020: 26 · 2019: 21 · 2018: 10 · 2017: 15 · 2016: 16 · 2015: 14 · 2014: 18 · 2013: 10 · 2012: 12
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Allergy and Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GlaxoSmithKline
- Sanofi
- Teva Pharmaceutical Industries
- National Institutes of Health
- Genentech
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- omalizumab, anaphylaxis, anaphylactoid reactions, drug hypersensitivity, post-marketing surveillance, clinical trial safety, patient education, prescribing recommendations
- MeSH terms
- Academies and Institutes, Omalizumab, Allergy and Immunology, Anaphylaxis, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Asthma, Humans, United States, Anti-Allergic Agents, Anti-Asthmatic Agents, Advisory Committees, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
